Table 2 Clinical information and anatomical site distribution on 200 cases of follicular lymphoma in young patients
From: Follicular lymphoma in young adults: a clinicopathological and molecular study of 200 patients
Extranodal FL | Nodal FL | Nodal FL+DLBCL | Total | |
|---|---|---|---|---|
Total (%(cases)) | 10(20) | 83(173) | 4(7) | 200 |
Age (years) | ||||
Median | 35 | 35 | 35 | 35 |
Range | 23–40 | 19–40 | 22–39 | 19–40 |
M:F | 9:11 | 75:98 | 3:4 | 87:113 |
Anatomic sites | Tonsil (5) | Abdominal (9) | Cervical (3) | — |
Duodenum (2) | Axillary (18) | Axillary (1) | — | |
Stomach (1) | Cervical (63) | Retroperitoneal (1) | — | |
Salivary gland (3) | Supraclavicular (7) | Mesenteric (1) | — | |
Justa-ureteral (1) | Inguinal (40) | Not specified (1) | — | |
Breast (1) | Mediastinal (1) | — | ||
Bone (2) | Mesenteric (6) | — | ||
Peritoneum (1) | Retroperitoneal (7) | — | ||
Lung (2) | Not specified (22) | — | ||
Thyroid (2) | — | |||
Clinical data (%(+)) | ||||
None | 40(8) | 40(70) | 14(1) | 40(79) |
Complete | 45(9) | 38(66) | 62(5) | 40(80) |
Only survival data | 15(3) | 22(37) | 14(1) | 20(41) |
Stage (%(+/tested)) | ||||
I | 55(5/9) | 14(10/71) | 20(1/5) | 19(16/85) |
II | 0 | 17(12/71) | 20(1/5) | 15(13/85) |
III | 0 | 28(20/71) | 20(1/5) | 25(21/85) |
IV | 45(4/9) | 41(29/71) | 40(2/5) | 41(35/85) |
B symptoms | 22(2/9) | 39(27/70) | 60(3/5) | 38(32/84) |
Elevated LDH level | 12(1/8) | 12(7/58) | 0/4 | 11(8/70) |
Anemia (HB <12 g/dl) | 0(0/8) | 17(10/60) | 0/4 | 14(10/72) |
Bone marrow involvement | 11(1/9) | 39(24/62) | 0/4 | 33(25/75) |
FLIPI score | ||||
Low risk (0–1) | 100(8/8) | 53(31/58) | 50(2/4) | 59(41/70) |
Intermediate (2) | 0 | 33(19/58) | 50(2/4) | 30(21/70) |
Poor risk (3–4) | 0 | 14(8/58) | 0 | 11(8/70) |
Chemotherapy | 7 | 63 | 5 | 75 |
CHOP+rituximab | 5 | 36 | 3 | 44 |
CVP+rituximab | — | 2 | — | 2 |
CHOP | 2 | 18 | 2 | 22 |
CVP | — | 1 | — | 1 |
Fludarabin | — | 3 | — | 3 |
MINE | — | 1 | — | 1 |
ProMACE-CytaBOM | — | 2 | — | 2 |
Watch and wait | — | 2 | — | 2 |
Radiation therapy | 4 | 18 | 1 | 23 |
Plus chemotherapy | 3 | 17 | 1 | 21 |
Radiation alone | 1 | 1 | — | 2 |
